Article by Business Wire
Responding to Canada’s opioid crisis, Delivra announced significant milestones over the past year which deliver opioid-free pain relief to Canadians. Delivra is a biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner.
Earlier this year, Delivra demonstrated the ability to deliver celecoxib (CelebrexTM) to provide sustained pain reduction, as its multi-layer liposomal system gradually releasing the medicine to the area of need. As such, topical Delivra-celecoxib (CelebrexTM) cream offers significant advantages to oral medication with better localization of the drug at the site of interest for quicker relief, longer lasting and using less drug.
Delivra is also finding success in Canada’s legal medical marijuana industry. This year Delivra has signed agreements with both Canopy Growth and Kalytera Therapeutics to bring cannabis and endocannabinoid-like treatments to market using innovative transdermal technologies.
“Cannabinoid therapy is a rapidly emerging field of medicine, quickly demonstrating its applicability to a range of acute and chronic indications, in particular, those related to pain management,” said Dr. Joseph Gabriele, founder and CEO of Delivra.
Many oral medications degrade during passage through the gastrointestinal tract. Delivra is helping to deliver beneficial cannabinoid compounds through the skin directly to affected areas.